Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26 juil. 2021 17h25 HE | Bellicum Pharmaceuticals, Inc.
HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity...
22157.jpg
Opportunities in the Global Monoclonal Antibodies Market: CAGR of Upwards of 11% Forecast with Market Set to Reach $179.56 Billion in 2025
26 juil. 2021 03h13 HE | Research and Markets
Dublin, July 26, 2021 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies (MAbS) Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's...
intrommune_icon_500x500.png
Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit
22 juil. 2021 16h57 HE | Intrommune Therapeutics
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
New Logo.png
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract at European Society for Medical Oncology (ESMO) Congress 2021
19 juil. 2021 07h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, July 19, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal disodium)...
22157.jpg
Global $2.93 Bn Head and Neck Cancer Therapeutics Markets to 2026 by Diagnostic Methods, Treatment Type, Disease Indication, Route of Administration, Therapeutic Class, End User
16 juil. 2021 04h03 HE | Research and Markets
Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Global Head and Neck Cancer Therapeutics Market By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others), By Treatment Type, By Disease Indication,...
FStar.jpg
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
08 juil. 2021 08h00 HE | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...
Logo-InveniAI.png
Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery Collaboration
06 juil. 2021 08h10 HE | InveniAI LLC
Collaboration to create transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®, with Sosei Heptares' GPCR Structure-based Drug Design and early...
WellNow Allergy Launches to Bring Convenience and Flexibility to Allergy Testing and Immunotherapy
06 juil. 2021 06h00 HE | WellNow Allergy
Buffalo, NY, July 06, 2021 (GLOBE NEWSWIRE) -- WellNow Allergy, an affiliate of leading urgent care provider WellNow Urgent Care, is now accepting patients in Western New York to provide allergy...
Picture1.png
Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
30 juin 2021 22h44 HE | Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a...
Rubius_Logo.jpg
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
23 juin 2021 16h01 HE | Rubius Therapeutics
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...